本文選題：燈盞乙素 + 聚乙二醇-聚乳酸/羥基乙酸共聚物　； 參考：《中國藥房》2015年19期

【摘要】：目的:制備燈盞乙素-聚乙二醇-聚乳酸/羥基乙酸共聚物(PEG-PLGA)載藥納米粒,優(yōu)化其處方,并進行質(zhì)量評價。方法:采用復乳-溶劑蒸發(fā)法制備燈盞乙素-PEG-PLGA載藥納米粒。以包封率為評價指標,以初乳與外水相的比例、燈盞乙素和PEG-PLGA質(zhì)量濃度為因素,通過單因素試驗和正交試驗優(yōu)化處方;測定最優(yōu)處方所制納米粒的表觀形態(tài)、粒徑、Zeta電位、載藥量、包封率和穩(wěn)定性。結(jié)果:最優(yōu)處方為初乳與外水相的比例1∶15,燈盞乙素質(zhì)量濃度10 mg/ml,PEG-PLGA質(zhì)量濃度15 mg/ml。所制得納米粒為圓形或橢圓形,平均粒徑為(78.54±2.21)nm,Zeta電位為(-23.07±1.39)m V,載藥量為(1.67±0.12)%,包封率為(45.32±1.29)%;納米粒在4℃下保存3個月內(nèi)粒徑和包封率無明顯變化。結(jié)論:成功制得具有較好理化性質(zhì)和穩(wěn)定性的燈盞乙素-PEG-PLGA納米粒。
[Abstract]:Aim: to prepare breviscapine-poly (ethylene glycol)-poly (lactic acid) / glycolic acid copolymers (PEG-PLGA) loaded nanoparticles, optimize their formulation and evaluate their quality. Methods: breviscapine-PEG-PLGA nanoparticles were prepared by double emulsion-solvent evaporation method. The encapsulation efficiency was used as the evaluation index, the ratio of colostrum to outer water, the mass concentration of breviscapine and PEG-PLGA as the factors, the formulation was optimized by single factor test and orthogonal test, the apparent morphology of the nanoparticles prepared by the optimal formulation was determined, and the particle size was determined by Zeta potential. Drug loading, encapsulation efficiency and stability. Results: the optimal formulation was 1: 15 for colostrum and 1: 15 for external water. The mass concentration of breviscapine was 10 mg / ml PEG-PLGA and 15 mg / ml. The average particle size was 78.54 鹵2.21nmGV, the average particle size was -23.07 鹵1.39mV, the drug loading was 1.67 鹵0.12mV, the entrapment efficiency was 45.32 鹵1.290.The particle size and entrapment efficiency had no significant change within 3 months after preservation at 4 鈩，

本文編號：2014330